Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel
NASDAQ:CRMD

CorMedix Q3 2026 Earnings Date & Estimates

CorMedix logo
$5.33 -0.14 (-2.49%)
As of 02:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CorMedix is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from CorMedix in Q3 2026

CorMedix is expected to post earnings of -$0.09 per share on revenue of $52.77 million. In the same quarter a year earlier CorMedix reported $1.26 per share on revenue of $104.28 million. CorMedix last reported on August 13, 2026, posting $0.29 per share and beating the $0.2380 consensus estimate. CorMedix has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.09
Expected Revenue
$52.77 million
Prior-Year EPS
$1.26
Prior-Year Revenue
$104.28 million
Expected EPS Growth
-107.1%
Expected Revenue Growth
-49.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.29 (Beat by +$0.0520)
Last Quarter Revenue
$101.93 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

CorMedix Q3 2026 Earnings FAQ

CorMedix (NASDAQ:CRMD) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

CorMedix's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect CorMedix to post earnings of -$0.09 per share for Q3 2026.

The consensus revenue estimate for CorMedix is $52.77 million for Q3 2026.

CorMedix Earnings Headlines

CorMedix stock gains as Heron deal adds four products
November 9 at 3:17 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/cormedix-stock-gains-heron-deal-135951284.html
CorMedix To Acquire Heron's Commercial Drug Portfolio In $223 Mln Deal; Stock Up
November 9 at 9:38 AM  |  rttnews.comhttps://www.rttnews.com/3711864/cormedix-to-acquire-heron-s-commercial-drug-portfolio-in-223-mln-deal-stock-up.aspx
My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
CorMedix, Heron Strike $223 Mln Upfront Asset Deal; Closing Expected In 2027; Stock Up
November 9 at 9:38 AM  |  rttnews.comhttps://www.rttnews.com/3711924/cormedix-heron-strike-223-mln-upfront-asset-deal-closing-expected-in-2027-stock-up.aspx
CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
November 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/06/3397502/0/en/cormedix-therapeutics-to-report-third-quarter-2026-financial-results-and-provide-a-corporate-update-on-november-12-2026.html
CorMedix reaffirms 2026 revenue guidance of $325 million–$345 million and reports $355 million cash position
November 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/cormedix-reaffirms-2026-revenue-guidance-of-325-million-345-million-and-reports-355-million-cash-position/ar-AA2gADew
See More CorMedix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email.

About CorMedix

CorMedix (NASDAQ:CRMD). is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat life-threatening infections and inflammatory conditions. The company’s lead product is DefenCath, a catheter-lock solution containing taurolidine and citrate.

DefenCath is approved by the U.S. Food and Drug Administration for use in adult patients with kidney failure who are receiving chronic hemodialysis through a central venous catheter. It is intended to reduce the risk of catheter-related bloodstream infections, a significant complication for patients who depend on long-term vascular access. CorMedix markets DefenCath in the United States through its commercial operations and continues to evaluate potential additional applications for its technology.

CorMedix was founded in 2006 and is headquartered in Berkeley Heights, New Jersey. The company is led by Khoso Bal, who serves as president and chief executive officer. Its business is primarily centered on the development and commercialization of anti-infective products for use in healthcare settings.

View CorMedix Profile
Earnings Tools